AVEO Pharmaceuticals Revenue 2010-2022 | AVEO

AVEO Pharmaceuticals revenue from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
AVEO Pharmaceuticals Annual Revenue
(Millions of US $)
2021 $42
2020 $6
2019 $29
2018 $5
2017 $8
2016 $3
2015 $19
2014 $18
2013 $1
2012 $19
2011 $165
2010 $45
2009 $21
AVEO Pharmaceuticals Quarterly Revenue
(Millions of US $)
2022-03-31 $21
2021-12-31 $18
2021-09-30 $15
2021-06-30 $8
2021-03-31 $2
2020-12-31 $1
2020-09-30 $4
2020-06-30 $1
2020-03-31 $1
2019-12-31 $1
2019-09-30 $26
2019-06-30 $1
2019-03-31 $2
2018-12-31 $1
2018-09-30 $2
2018-06-30 $0
2018-03-31 $1
2017-12-31 $0
2017-09-30 $5
2017-06-30 $0
2017-03-31 $3
2016-12-31 $0
2016-09-30 $1
2016-06-30 $0
2016-03-31 $1
2015-12-31 $4
2015-09-30 $15
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $1
2014-06-30 $2
2014-03-31 $15
2013-12-31 $0
2013-09-30 $0
2013-06-30 $0
2013-03-31 $0
2012-12-31 $16
2012-09-30 $1
2012-06-30 $2
2012-03-31 $1
2011-12-31 $1
2011-09-30 $4
2011-06-30 $27
2011-03-31 $134
2010-12-31 $12
2010-09-30 $6
2010-06-30 $16
2010-03-31 $11
2009-12-31 $6
2009-09-30 $6
2009-06-30 $5
2009-03-31 $4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.146B $0.042B
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00